CRIS Current Research Information System

BALDAZZI, CARMEN
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.723
AS - Asia 5.424
EU - Europa 4.068
AF - Africa 365
Continente sconosciuto - Info sul continente non disponibili 290
SA - Sud America 268
OC - Oceania 9
Totale 16.147
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.571
VN - Vietnam 1.721
SG - Singapore 1.316
CN - Cina 1.229
GB - Regno Unito 1.033
SE - Svezia 631
IT - Italia 601
DE - Germania 489
HK - Hong Kong 328
FR - Francia 260
IN - India 232
RU - Federazione Russa 195
BR - Brasile 185
NL - Olanda 159
IE - Irlanda 141
KR - Corea 123
UA - Ucraina 96
FI - Finlandia 90
CA - Canada 88
ZA - Sudafrica 88
JP - Giappone 87
TG - Togo 79
EE - Estonia 75
CI - Costa d'Avorio 64
NG - Nigeria 58
CH - Svizzera 57
BG - Bulgaria 52
JO - Giordania 51
GR - Grecia 45
SC - Seychelles 44
PH - Filippine 42
IR - Iran 40
AR - Argentina 33
BD - Bangladesh 33
TR - Turchia 31
BE - Belgio 30
ID - Indonesia 29
IQ - Iraq 27
TH - Thailandia 26
PL - Polonia 22
AT - Austria 21
EU - Europa 21
MX - Messico 21
TW - Taiwan 18
ES - Italia 16
UZ - Uzbekistan 16
EC - Ecuador 15
MY - Malesia 15
CO - Colombia 10
HR - Croazia 10
AU - Australia 8
JM - Giamaica 8
PK - Pakistan 8
PY - Paraguay 8
RO - Romania 8
TM - Turkmenistan 8
VE - Venezuela 8
KE - Kenya 7
LT - Lituania 7
SA - Arabia Saudita 7
CR - Costa Rica 6
HN - Honduras 6
MA - Marocco 6
MU - Mauritius 6
BB - Barbados 5
CL - Cile 5
IL - Israele 5
LB - Libano 5
AL - Albania 4
EG - Egitto 4
MK - Macedonia 4
PT - Portogallo 4
SV - El Salvador 4
KH - Cambogia 3
KZ - Kazakistan 3
NI - Nicaragua 3
PE - Perù 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
CY - Cipro 2
CZ - Repubblica Ceca 2
GP - Guadalupe 2
GT - Guatemala 2
KG - Kirghizistan 2
KW - Kuwait 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
NO - Norvegia 2
PR - Porto Rico 2
RS - Serbia 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AG - Antigua e Barbuda 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
Totale 15.860
Salva come PNG Salva come JPEG
Città #
Southend 935
Singapore 933
Ashburn 591
Dong Ket 589
Chandler 470
Fairfield 417
San Jose 311
Hong Kong 308
Ann Arbor 257
Houston 241
Wilmington 238
Ho Chi Minh City 232
Hanoi 218
Seattle 203
Beijing 200
Woodbridge 196
Hefei 194
Princeton 165
Santa Clara 161
Cambridge 153
Dublin 141
Boardman 127
Seoul 103
New York 90
Council Bluffs 86
Nanjing 83
Lauterbourg 80
Lomé 79
Westminster 78
Bologna 77
Los Angeles 73
Padova 71
Tokyo 69
Abidjan 64
Helsinki 61
Medford 55
Milan 55
Amman 50
Berlin 50
Sofia 49
Bern 46
Munich 45
Abeokuta 39
Bremen 39
Buffalo 38
Shenyang 38
Jinan 37
Dallas 36
Haiphong 34
Saint Petersburg 34
Chicago 33
Frankfurt am Main 33
Turin 33
São Paulo 32
Hebei 31
Nanchang 30
Brussels 29
Phoenix 28
Redondo Beach 28
Da Nang 27
Florence 26
Guangzhou 26
Changsha 25
Rome 25
San Diego 25
Jacksonville 24
Hangzhou 22
Shanghai 22
Orem 21
Paris 21
Redwood City 21
Toronto 21
Bengaluru 19
Falls Church 19
Montreal 19
Falkenstein 18
Tianjin 18
Mountain View 17
Brooklyn 16
Hải Dương 16
Istanbul 16
Johannesburg 16
Lappeenranta 16
Athens 14
Atlanta 14
Jakarta 14
London 13
Nuremberg 13
Vienna 13
Zhengzhou 13
Baghdad 12
Biên Hòa 12
Fuzhou 12
Jiaxing 12
Norwalk 12
Bangkok 11
Haikou 11
Hyderabad 11
Tehran 11
Wuhan 11
Totale 9.921
Salva come PNG Salva come JPEG
Nome #
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 417
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 362
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 353
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 351
4q12 translocations with GSX2 expression identify a CD7+ acute myeloid leukaemia subset 345
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 325
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 309
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 296
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 284
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 268
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 260
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 258
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 253
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 249
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 247
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 239
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 239
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 233
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 231
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 223
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 220
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 216
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 216
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 216
A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia 215
t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities 212
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 210
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 209
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 208
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 207
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 201
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 200
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway 198
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 197
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 197
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 194
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 191
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 187
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 187
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 187
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 186
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 186
A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 184
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 183
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 181
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 181
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 178
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 178
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 178
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 178
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 172
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 167
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 166
You have accessA New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 166
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 165
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 163
Novel fusion transcripts identified by RNAseq cooperate with somatic mutations in the pathogenesis of acute myeloid leukemia 161
Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels 160
FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features 158
Next-Generation Sequencing Analysis Revealed That BCL11B Chromosomal Translocation Cooperates with Point Mutations in the Pathogenesis of Acute Myeloid Leukemia 157
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 156
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 155
Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harbouring FLT3 Mutations in AML Patients 153
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 150
IKZF1 (IKAROS) DELETIONS IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ARE ASSOCIATED WITH AN IMPAIRED B-CELL DIFFERENTIATION AND POOR OUTCOME 147
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients 147
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 146
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 140
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP) 139
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). 138
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 137
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 134
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 133
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 133
PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients 133
NELARABINE IS SAFE AND EFFECTIVE IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 133
IDENTIFICATION OF FREQUENT GENOMIC ABNORMALITIES IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS USING SINGLE NUCLEOTIDE POLYMORPHISM ARRAYS 131
IKZF1 (IKAROS) DELETIONS ARE A CENTRAL EVENT IN THE PATHOGENESIS OF BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 125
SINGLE NUCLEOTIDE POLYMORPHISM (SNP) ARRAYS IDENTIFIED FREQUENT GENOMIC ABNORMALITIES IN GENES INVOLVED IN DRUG TRANSPORT AND INHIBITION OF APOPTOSIS IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS 124
NILOTINIB 400 MG BID IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: BEYOND 4 YEARS RESULTS REMAIN STABLE - THE GIMEMA CML WP TRIAL CML0307 122
IKZF1 (IKAROS) DELETIONS ARE INDEPENDENT ON THE PHILADELPHIA CHROMOSOME AND ARE ASSOCIATED WITH AN IMPAIRED B-CELL DIFFERENTIATION AND POOR OUTCOME IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 113
Totale 16.147
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.173
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.173
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.567 0 0 101 180 179 103 37 95 95 150 328 299
2022/20231.979 220 311 118 258 134 159 47 108 329 49 153 93
2023/2024589 23 74 28 68 39 149 36 52 21 31 38 30
2024/20252.011 71 297 177 125 241 72 197 66 14 242 114 395
2025/20264.596 429 408 354 293 467 216 401 175 1.127 443 127 156
2026/2027607 139 163 305 0 0 0 0 0 0 0 0 0
Totale 16.147